Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
250 mg capsule, 250 mg tablets · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | 500 mg LX1033, capsules administered two times per day orally |
| Treatment B | EXPERIMENTAL | 500 mg LX1033, tablets administered two times per day orally |
| Name | Type | Description |
|---|---|---|
| 250 mg capsule | DRUG | Two 250 mg capsules will be administered for 500 mg dose |
| 250 mg tablets | DRUG | Two 250 mg tablets will be administered for a 500 mg dose |
Inclusion Criteria: * Adult subjects age 18 to 55 years * Vital signs acceptable at Screening * Body mass index (BMI) between 18 and 35 kg/m\^2 at Screening * Considered to be in good health, as determined by the Investigator * Normal ECG findings * Negative urine screen for drugs of abuse and nega...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Ardelyx, Inc. | ARDX | 3 | PHASE3 | Tenapanor |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | - | Undisclosed |
| Johnson & Johnson | JNJ | 1 | - | Anti TNF therapy including infliximab, No Biologics |
| Cooper Companies, Inc. | COO | 1 | N/A | Undisclosed |
LX1033 is an investigational drug being studied for the treatment of Irritable Bowel Syndrome. It is currently in Phase 1 clinical development and has been evaluated in a completed clinical trial involving healthy volunteers.
LX1033 is being developed by Lexicon Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol LXRX. The company is conducting clinical research on this investigational drug for gastrointestinal conditions.
LX1033 is in Phase 1 clinical development. A Phase 1 study of the drug has been completed, and it remains an investigational agent that has not yet been approved by regulatory authorities.
LX1033 has been studied in a completed Phase 1 clinical trial registered as NCT01411800. This open-label study evaluated two formulations of LX1033 in 28 healthy human subjects in the United States, with participants aged 18 years and older.
LX1033 is the drug name used in clinical research. The completed trial NCT01411800 evaluated two different formulations of LX1033, both administered as 250 mg capsules or tablets, to compare their properties in healthy subjects.